MindWalk unveils B Cell Llama nanobody platform

MindWalk Holdings Corp. introduced B Cell Llama™, a new platform to discover VHH nanobodies, the single‑domain antibody fragments used in bispecific antibodies, multispecific drugs, and CAR‑T cell therapies.

Rhea-AI Filing Summary

MindWalk Holdings Corp. introduced B Cell Llama™, a new platform to discover VHH nanobodies, the single‑domain antibody fragments used in bispecific antibodies, multispecific drugs, and CAR‑T cell therapies. The platform extends the company’s existing B Cell Select® technology into llama‑derived antibodies.

A peer‑reviewed study in ACS Biomacromolecules underpins the launch, showing multivalent VHH formats achieved sub‑nanomolar potency, restored activity against resistant variants, and suggested a potential immune‑priming effect. The work also showed that strong binding alone did not guarantee functional activity, supporting MindWalk’s LensAI™ focus on function‑based candidate selection.

The company positions B Cell Llama™ within a broader bio‑native AI strategy that already supports programs in dengue, universal influenza, GLP‑1 and longevity therapeutics, ALK‑1 oncology and rare disease, and other nanobody therapeutics, while holding first rights to commercialize jointly developed intellectual property from the collaboration.

Insights

Biotech and AI drug discovery analyst

MindWalk links a new nanobody platform to peer‑reviewed data and its AI engine.

MindWalk Holdings Corp. is showcasing B Cell Llama™, a VHH nanobody discovery platform built on its B Cell Select® infrastructure. It focuses on llama‑derived single‑domain antibodies, which are attractive building blocks for bispecifics, multispecifics, and CAR‑T therapies, markets cited as reaching tens of billions of dollars.

The supporting Biomacromolecules study highlights three attributes: multivalent VHH formats delivered sub‑nanomolar potency with 10–25‑fold gains over monovalent versions, modular constructs neutralized variants that resisted monovalent formats and approved therapies, and VHH‑nanoparticle complexes were internalized by immune‑memory‑linked cells, suggesting a possible immune‑priming effect.

The work also found that the tightest binder had no functional activity, reinforcing MindWalk’s emphasis on LensAI™ ranking candidates by function, not binding alone. The platform fits into a pipeline spanning dengue, universal influenza, GLP‑1 and longevity therapeutics, ALK‑1, and nanobody programs; future disclosures and clinical data will determine how much value this adds.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MindWalk Holdings Corp. (IPA) announce with B Cell Llama™?

MindWalk announced B Cell Llama™, a nanobody discovery platform focused on llama‑derived VHH single‑domain antibodies. It targets applications in bispecific antibodies, multispecific therapeutics, and CAR‑T cell therapies, extending the company’s existing B Cell Select® infrastructure into a dedicated VHH capability supported by its LensAI™ system.

How is the B Cell Llama™ platform validated according to MindWalk (IPA)?

B Cell Llama™ is supported by a peer‑reviewed study in ACS Biomacromolecules. The research, done with Eindhoven University of Technology and Radboud University Medical Center, showed multivalent VHH constructs with sub‑nanomolar potency, activity against resistant variants, and a possible immune‑priming effect via VHH‑nanoparticle complexes.

What role does LensAI™ play in MindWalk’s (IPA) B Cell Llama™ platform?

LensAI™ is designed to guide the full B Cell Llama™ workflow, from target and immunogen design to candidate triage, multispecific construct modeling, and immunogenicity assessment. It emphasizes ranking candidates by functional activity rather than binding strength alone, reflecting findings from the Biomacromolecules study.

How does B Cell Llama™ differ from MindWalk’s existing B Cell Select® technology (IPA)?

B Cell Select® isolates antibody‑producing B cells from immunized rabbits, whereas B Cell Llama™ does the same from immunized llamas to capture VHH nanobodies. This approach taps naturally matured llama immune repertoires, aiming for sequence diversity that synthetic libraries and transgenic platforms may not match structurally.

What therapeutic areas are in MindWalk Holdings Corp. (IPA) pipeline?

MindWalk’s pipeline includes dengue covering all four serotypes, a universal influenza program targeting conserved cross‑strain regions, GLP‑1 and longevity therapeutics with a first‑in‑class dual‑pathway regimen, and ALK‑1 programs in oncology and rare disease, alongside broader nanobody therapeutic initiatives linked to B Cell Llama™.

What forward-looking cautions does MindWalk (IPA) provide about B Cell Llama™ and LensAI™?

MindWalk notes that described LensAI™ capabilities reflect design intentions and are not all fully integrated into current workflows. It cautions that preclinical and in vitro results, including potential immune‑priming effects and cited market projections, may not translate into clinical success or realized commercial outcomes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 04:03 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of March, 2026.

Commission File Number: 001-39530

MindWalk Holdings Corp.

3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit	Description
99.1	Press Release dated March 6, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MINDWALK HOLDINGS CORP.
Date: March 6, 2026
	By:	/s/ Jennifer Bath
	Name:	Jennifer Bath
	Title:	President and Chief Executive Officer

99.1

MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era

Peer-reviewed study in ACS Biomacromolecules demonstrates modular VHH potency, cross-variant therapeutic activity, and a newly described immune-priming mechanism; MindWalk holds first right to commercialize jointly developed intellectual property

AUSTIN, TX | MindWalk Holdings Corp. (NASDAQ: HYFT), a bio-native AI company, today announced B Cell Llama™, a platform for the discovery of VHH nanobodies: the single-domain antibody fragments increasingly recognized as the ideal molecular building blocks for bispecific antibodies, multispecific therapeutics, and CAR-T cell therapies. Bispecific antibody sales alone are projected to reach US$50 billion by 2030, with the broader cell therapy market adding tens of billions more. B Cell Llama™ is designed to help partners capture this opportunity with better starting material and AI-guided precision at every step of the discovery process.

"VHH nanobodies solve the molecular engineering problem that has made bispecific and multispecific drug development so difficult for so long. B Cell Llama™ extends our flagship B Cell Select® platform into the distinct biology of llama-derived single-domain antibodies, adding a dedicated VHH capability to the broader MindWalk ecosystem that has supported the advancement of over 15 molecules to the clinic across our technologies. What sets it apart is the ability to layer LensAI™ across the entire discovery process: guiding target selection before immunization begins, triaging candidates by predicted function, and evaluating multispecific constructs in silico before a single molecule is built in the lab."

Dr. Jennifer Bath, Chief Executive Officer, MindWalk Holdings Corp.

Peer-Reviewed Validation

The announcement is anchored by a study published in Biomacromolecules (American Chemical Society, 2026), conducted by MindWalk in a grant-funded collaboration with Eindhoven University of Technology and Radboud University Medical Center. Three findings from the study illustrate what modular VHH design can achieve:

•Potency amplified through assembly. Nanobodies displayed in multivalent formats achieved sub-nanomolar potency, 10 to 25 times greater than the same nanobody in monovalent form.

•Modular reconfiguration defeats resistance. A trivalent VHH construct neutralized variants that escaped all monovalent formats and defeated a pair of approved antibody therapies, demonstrating that rational reassembly of the same building block can restore activity where single agents fail.

•A potential immune-priming effect. VHH-nanoparticle complexes were preferentially internalized by immune cells associated with long-term immune memory, raising the possibility that certain VHH formats may not only neutralize a target but help the immune system recognize it in the future.

The study also produced a finding with direct relevance to AI-guided drug discovery: the molecule with the strongest binding affinity delivered zero functional activity. Binding strength is not a reliable proxy for efficacy. Some conventional discovery workflows depend heavily on binding metrics to rank and select candidates. LensAI™ is designed to prioritize function directly.

About B Cell Llama™

B Cell Llama™ builds on the proven infrastructure of B Cell Select®, one of the technologies within MindWalk's broader platform ecosystem. Where B Cell Select® isolates antibody-producing B cells from immunized rabbits, B Cell Llama™ does the same from immunized llamas, capturing VHH nanobodies directly from a naturally matured immune repertoire. This approach accesses a breadth and quality of sequence diversity that synthetic display libraries cannot replicate and that genetically constrained transgenic platforms structurally limit. LensAI™ can then be applied across the full workflow: from immunogen design through candidate triage, multispecific construct modeling, and immunogenicity assessment.

Pipeline Context

B Cell Llama™ is one expression of MindWalk's bio-native AI strategy, which is advancing programs across multiple therapeutic areas. Current programs include dengue (all four serotypes; advancing to manufacturing), universal influenza (conserved cross-strain target identified), GLP-1 and longevity therapeutics (first-in-class dual-pathway regimen; IP protection initiated), and ALK-1 (oncology and rare disease). Additional programs are in development.

About the Study

Le, D.H.T. et al. Biomacromolecules 2026, 27(2), 1446-1458. DOI: 10.1021/acs.biomac.5c02042. Conducted in collaboration with Eindhoven University of Technology and Radboud University Medical Center, supported by Health Holland (Project LSHM20078) under the Eureka Program. MindWalk holds first right to protect and commercialize jointly generated intellectual property.

About MindWalk Holdings Corp.

MindWalk Holdings Corp. (NASDAQ: HYFT) is a bio-native AI company transforming the discovery and development of therapeutics, vaccines, and diagnostics. The Company's proprietary HYFT® technology and LensAI™ platform make biological diversity computable and actionable, integrating sequence, structure, function, and literature into a unified computational language. MindWalk's technologies have supported the advancement of over 15 molecules to clinical stage. Current programs span dengue, universal influenza, GLP-1 and longevity therapeutics, oncology, and nanobody therapeutics. For more information, visit www.mindwalkai.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. Forward-looking statements include those regarding the capabilities and potential of B Cell Llama™ and LensAI™, pipeline program progress, market projections, and the potential for an

immune-priming effect from VHH-nanoparticle formats. LensAI™ capabilities described herein represent design intentions and have not all been fully integrated into current operational protocols. Preclinical and in vitro results may not translate to clinical success. Market estimates are based on third-party projections and may not be realized. The Company disclaims any obligation to update forward-looking statements except as required by law. See the Company's annual report on Form 20-F at www.sedarplus.ca and www.sec.gov/edgar.

Investor Relations: Louie Toma, CPA, CFA | Managing Director, CoreIR | investors@mindwalkai.com

Source: MindWalk Holdings Corp.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 24.3 KB